Dana Backlund Cardin, M.D.

Associate Professor

Faculty Appointments
Associate Professor of Medicine
M.S.C.I., Clinical Investigation, Vanderbilt University, Nashville, TennesseeM.D., University of North Carolina, Chapel Hill, North CarolinaB.S., University of North Carolina School of Medicine, Chapel Hill, North Carolina
Office Address
2220 Pierce Avenue
777 PRB
Nashville, TN 37232
Research Description
After receiving her undergraduate degree in Biology from the University of North Carolina, Dr. Cardin worked for two years in a translational research lab that used gene targeting techniques to create mouse modeling systems to better understand human disease. After this invaluable research experience, she attended medical school at the University of North Carolina, and went on to match at NYU in Diagnostic Radiology. Dr. Cardin did her internship in Internal Medicine at Mt. Sinai Hospital in New York, NY, and this year of patient care led her to switch paths and she subsequently came to Vanderbilt University Medical Center to complete her residency in Internal Medicine. She completed her Fellowship in Hematology/Oncology in 2009, after serving for one year as the Carol and James O'Hare Chief Fellow. She completed a Master of Science in Clinical Investigation at Vanderbilt in 2010.

Dr. Cardin specializes in malignancies of the gastrointestinal tract with a research interest in phase I and pancreas cancer trials. She is an active member of the American Society of Clinical Oncology and the American Association for Cancer Research
Chan E, Goff LW, Cardin DB, Ancell K, Smith SJ, Whisenant JG, Ye F, Berlin JD. Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS. Invest New Drugs [print-electronic]. 2017 Aug; 35(4): 491-8. PMID: 28353122, PII: 10.1007/s10637-017-0458-8, DOI: 10.1007/s10637-017-0458-8, ISSN: 1573-0646.

Cardin DB, Thota R, Goff LW, Berlin JD, Jones CM, Ayers GD, Whisenant JG, Chan E. A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer. Am. J. Clin. Oncol [print-electronic]. 2017 Mar 3/15/2017; PMID: 28301350, DOI: 10.1097/COC.0000000000000377, ISSN: 1537-453X.

Goff LW, Cardin DB, Whisenant JG, Du L, Koyama T, Dahlman KB, Salaria SN, Young RT, Ciombor KK, Gilbert J, Smith SJ, Chan E, Berlin J. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers. Invest New Drugs [print-electronic]. 2017 Feb; 35(1): 95-104. PMID: 27853997, PMCID: PMC5306261, PII: 10.1007/s10637-016-0406-z, DOI: 10.1007/s10637-016-0406-z, ISSN: 1573-0646.

Cardin DB, Goff L, Li CI, Shyr Y, Winkler C, DeVore R, Schlabach L, Holloway M, McClanahan P, Meyer K, Grigorieva J, Berlin J, Chan E. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. Cancer Med [print-electronic]. 2014 Jun; 3(3): 572-9. PMID: 24574334, PMCID: PMC4101748, DOI: 10.1002/cam4.208, ISSN: 2045-7634.

Goff LW, Thakkar N, Du L, Chan E, Tan BR, Cardin DB, McLeod HL, Berlin JD, Zehnbauer B, Fournier C, Picus J, Wang-Gillam A, Lee W, Lockhart AC. Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers. PLoS ONE. 2014; 9(9): e107424. PMID: 25232828, PMCID: PMC4169411, PII: PONE-D-14-22736, DOI: 10.1371/journal.pone.0107424, ISSN: 1932-6203.

Cardin DB, Berlin JD. Pancreas cancer on the rise: are we up to the challenge? [editorial]. J. Natl. Cancer Inst [print-electronic]. 2013 Nov 11/20/2013; 105(22): 1675-6. PMID: 24203986, PII: djt316, DOI: 10.1093/jnci/djt316, ISSN: 1460-2105.

Castellanos E, Berlin J, Cardin DB. Current treatment options for pancreatic carcinoma. Curr Oncol Rep. 2011 Jun; 13(3): 195-205. PMID: 21491194, DOI: 10.1007/s11912-011-0164-1, ISSN: 1534-6269.

Castellanos EH, Cardin DB, Berlin JD. Treatment of early-stage pancreatic cancer. Oncology (Williston Park, N.Y.). 2011 Feb; 25(2): 182-9. PMID: 21456390, PII: 167379, ISSN: 0890-9091.

Backlund DC, Berlin JD, Parikh AA. Update on adjuvant trials for pancreatic cancer. Surg. Oncol. Clin. N. Am. 2010 Apr; 19(2): 391-409. PMID: 20159521, PII: S1055-3207(09)00118-5, DOI: 10.1016/j.soc.2009.11.003, ISSN: 1558-5042.

Cressman VL, Backlund DC, Avrutskaya AV, Leadon SA, Godfrey V, Koller BH. Growth retardation, DNA repair defects, and lack of spermatogenesis in BRCA1-deficient mice. Mol. Cell. Biol. 2006 Dec; 26(24): 9571. PMID: 17135280, PMCID: PMC1698514, PII: 26/24/9571, DOI: 10.1128/MCB.01939-06, ISSN: 0270-7306.

Brown SA, Ontjes DA, Lester GE, Lark RK, Hensler MB, Blackwood AD, Caminiti MJ, Backlund DC, Aris RM. Short-term calcitriol administration improves calcium homeostasis in adults with cystic fibrosis. Osteoporos Int [print-electronic]. 2003 Jun; 14(5): 442-9. PMID: 12774194, DOI: 10.1007/s00198-002-1331-x, ISSN: 0937-941X.

Backlund MG, Trasti SL, Backlund DC, Cressman VL, Godfrey V, Koller BH. Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice. Cancer Res. 2001 Sep 9/1/2001; 61(17): 6577-82. PMID: 11522657, ISSN: 0008-5472.

Cressman VL, Backlund DC, Avrutskaya AV, Leadon SA, Godfrey V, Koller BH. Growth retardation, DNA repair defects, and lack of spermatogenesis in BRCA1-deficient mice. Mol. Cell. Biol. 1999 Oct; 19(10): 7061-75. PMID: 10490643, PMCID: PMC84701, ISSN: 0270-7306.

Cressman VL, Backlund DC, Hicks EM, Gowen LC, Godfrey V, Koller BH. Mammary tumor formation in p53- and BRCA1-deficient mice. Cell Growth Differ. 1999 Jan; 10(1): 1-10. PMID: 9950212, ISSN: 1044-9523.

Cressman VL, Hicks EM, Funkhouser WK, Backlund DC, Koller BH. The relationship of chronic mucin secretion to airway disease in normal and CFTR-deficient mice. Am. J. Respir. Cell Mol. Biol. 1998 Dec; 19(6): 853-66. PMID: 9843919, DOI: 10.1165/ajrcmb.19.6.3194, ISSN: 1044-1549.